Cargando…

The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease

A longitudinal molecular model of the development and progression of nonalcoholic fatty liver disease (NAFLD) over time is lacking. We have recently validated a high fat/sugar water-induced animal (an isogenic strain of C57BL/6 J:129S1/SvImJ mice) model of NAFLD that closely mimics most aspects of h...

Descripción completa

Detalles Bibliográficos
Autores principales: Cazanave, Sophie, Podtelezhnikov, Alexei, Jensen, Kristian, Seneshaw, Mulugeta, Kumar, Divya P., Min, Hae-Ki, Santhekadur, Prasanna K., Banini, Bubu, Mauro, Adolfo Gabriele, M. Oseini, Abdul, Vincent, Robert, Tanis, Keith Q., Webber, Andrea L., Wang, Liangsu, Bedossa, Pierre, Mirshahi, Faridoddin, Sanyal, Arun J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722878/
https://www.ncbi.nlm.nih.gov/pubmed/29222421
http://dx.doi.org/10.1038/s41598-017-17370-6
_version_ 1783285095071744000
author Cazanave, Sophie
Podtelezhnikov, Alexei
Jensen, Kristian
Seneshaw, Mulugeta
Kumar, Divya P.
Min, Hae-Ki
Santhekadur, Prasanna K.
Banini, Bubu
Mauro, Adolfo Gabriele
M. Oseini, Abdul
Vincent, Robert
Tanis, Keith Q.
Webber, Andrea L.
Wang, Liangsu
Bedossa, Pierre
Mirshahi, Faridoddin
Sanyal, Arun J.
author_facet Cazanave, Sophie
Podtelezhnikov, Alexei
Jensen, Kristian
Seneshaw, Mulugeta
Kumar, Divya P.
Min, Hae-Ki
Santhekadur, Prasanna K.
Banini, Bubu
Mauro, Adolfo Gabriele
M. Oseini, Abdul
Vincent, Robert
Tanis, Keith Q.
Webber, Andrea L.
Wang, Liangsu
Bedossa, Pierre
Mirshahi, Faridoddin
Sanyal, Arun J.
author_sort Cazanave, Sophie
collection PubMed
description A longitudinal molecular model of the development and progression of nonalcoholic fatty liver disease (NAFLD) over time is lacking. We have recently validated a high fat/sugar water-induced animal (an isogenic strain of C57BL/6 J:129S1/SvImJ mice) model of NAFLD that closely mimics most aspects of human disease. The hepatic transcriptome of such mice with fatty liver (8 weeks), steatohepatitis with early fibrosis (16–24 weeks) and advanced fibrosis (52 weeks) after initiation of the diet was evaluated and compared to mice on chow diet. Fatty liver development was associated with transcriptional activation of lipogenesis, FXR-RXR, PPAR-α mediated lipid oxidation and oxidative stress pathways. With progression to steatohepatitis, metabolic pathway activation persisted with additional activation of IL-1/inhibition of RXR, granulocyte diapedesis/adhesion, Fc macrophage activation, prothrombin activation and hepatic stellate cell activation. Progression to advanced fibrosis was associated with dampening of metabolic, oxidative stress and cell stress related pathway activation but with further Fc macrophage activation, cell death and turnover and activation of cancer-related networks. The molecular progression of NAFLD involves a metabolic perturbation which triggers subsequent cell stress and inflammation driving cell death and turnover. Over time, inflammation and fibrogenic pathways become dominant while in advanced disease an inflammatory-oncogenic profile dominates.
format Online
Article
Text
id pubmed-5722878
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-57228782017-12-12 The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease Cazanave, Sophie Podtelezhnikov, Alexei Jensen, Kristian Seneshaw, Mulugeta Kumar, Divya P. Min, Hae-Ki Santhekadur, Prasanna K. Banini, Bubu Mauro, Adolfo Gabriele M. Oseini, Abdul Vincent, Robert Tanis, Keith Q. Webber, Andrea L. Wang, Liangsu Bedossa, Pierre Mirshahi, Faridoddin Sanyal, Arun J. Sci Rep Article A longitudinal molecular model of the development and progression of nonalcoholic fatty liver disease (NAFLD) over time is lacking. We have recently validated a high fat/sugar water-induced animal (an isogenic strain of C57BL/6 J:129S1/SvImJ mice) model of NAFLD that closely mimics most aspects of human disease. The hepatic transcriptome of such mice with fatty liver (8 weeks), steatohepatitis with early fibrosis (16–24 weeks) and advanced fibrosis (52 weeks) after initiation of the diet was evaluated and compared to mice on chow diet. Fatty liver development was associated with transcriptional activation of lipogenesis, FXR-RXR, PPAR-α mediated lipid oxidation and oxidative stress pathways. With progression to steatohepatitis, metabolic pathway activation persisted with additional activation of IL-1/inhibition of RXR, granulocyte diapedesis/adhesion, Fc macrophage activation, prothrombin activation and hepatic stellate cell activation. Progression to advanced fibrosis was associated with dampening of metabolic, oxidative stress and cell stress related pathway activation but with further Fc macrophage activation, cell death and turnover and activation of cancer-related networks. The molecular progression of NAFLD involves a metabolic perturbation which triggers subsequent cell stress and inflammation driving cell death and turnover. Over time, inflammation and fibrogenic pathways become dominant while in advanced disease an inflammatory-oncogenic profile dominates. Nature Publishing Group UK 2017-12-08 /pmc/articles/PMC5722878/ /pubmed/29222421 http://dx.doi.org/10.1038/s41598-017-17370-6 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Cazanave, Sophie
Podtelezhnikov, Alexei
Jensen, Kristian
Seneshaw, Mulugeta
Kumar, Divya P.
Min, Hae-Ki
Santhekadur, Prasanna K.
Banini, Bubu
Mauro, Adolfo Gabriele
M. Oseini, Abdul
Vincent, Robert
Tanis, Keith Q.
Webber, Andrea L.
Wang, Liangsu
Bedossa, Pierre
Mirshahi, Faridoddin
Sanyal, Arun J.
The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
title The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
title_full The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
title_fullStr The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
title_full_unstemmed The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
title_short The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
title_sort transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722878/
https://www.ncbi.nlm.nih.gov/pubmed/29222421
http://dx.doi.org/10.1038/s41598-017-17370-6
work_keys_str_mv AT cazanavesophie thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT podtelezhnikovalexei thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT jensenkristian thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT seneshawmulugeta thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT kumardivyap thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT minhaeki thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT santhekadurprasannak thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT baninibubu thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT mauroadolfogabriele thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT moseiniabdul thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT vincentrobert thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT taniskeithq thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT webberandreal thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT wangliangsu thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT bedossapierre thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT mirshahifaridoddin thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT sanyalarunj thetranscriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT cazanavesophie transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT podtelezhnikovalexei transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT jensenkristian transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT seneshawmulugeta transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT kumardivyap transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT minhaeki transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT santhekadurprasannak transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT baninibubu transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT mauroadolfogabriele transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT moseiniabdul transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT vincentrobert transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT taniskeithq transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT webberandreal transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT wangliangsu transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT bedossapierre transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT mirshahifaridoddin transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease
AT sanyalarunj transcriptomicsignatureofdiseasedevelopmentandprogressionofnonalcoholicfattyliverdisease